Methods: This retrospective study used data from the Medical Data Vision Co., Ltd.database, including patients (18 years) with a confirmed diagnosis of stage I-III, hormone receptor-positive, and human epidermal growth factor receptor 2-negative EBC who received abemaciclib as adjuvant therapy between December 2021 and November 2024.The 2-year follow-up population was defined as patients with an index period 2 years, measured from the index date (the date of first prescription of abemaciclib) to the later of either the last hospital visit or the final prescription date (last prescription date + days supplied).Patient characteristics and treatment patterns such as 2-year adjuvant abemaciclib and endocrine therapy (ET) completion rates, starting dose, and dose modifications were summarized descriptively.Results: Of the 2042 eligible patients, 439 patients (median age min-max of 55 (26-84) years and 99.3% being females) had a 2-year follow-up.Of these, 70.6% (n = 310/439) of patients completed adjuvant abemaciclib and ET for 2 years.Approximately 21.9% (n = 96/439) discontinued abemaciclib within 2 years but continued ET.Additionally, 7.5% (n = 33/439) discontinued both abemaciclib and ET within 2 years.Among patients who had a 2-year follow-up, 92.3% (n = 405/439) received abemaciclib at an initial dose of 300mg/day, and 58.3% (n = 256/439) experienced dose reductions.Conclusions: Approximately 71% of patients successfully completed abemaciclib plus ET in 2 years, with 58% having a dose modification.These results demonstrate the treatment continuity of abemaciclib among patients with EBC when dose modifications are utilized in real-world clinical practice in Japan.
Kucharczak et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: